REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)
REal World Advanced Experience of BioResorbable ScaffolD by SMart Angioplasty Research Team (SMART REWARD)
Current drug-eluting stents (DES) has demonstrated excellent clinical outcomes in patients
 with coronary artery disease. However, a continued risk of clinical events even several years
 after the procedure is reported. Stent platform or polymer-associated inflammation may play a
 role.

 Bioresorbable scaffold (BRS) is known to disappear 2 to 3 years after the implantation, which
 may result in the more favorable very long-term clinical outcomes compared with metallic
 stents. The initial clinical experiences of BRS in relatively simple lesion subsets were
 comparable to DESs.

 BRS, however, is limited by the disadvantageous mechanical characteristics such as thick
 strut and the risk of fracture by overdilation. There is concern that BRS is less optimal for
 complex lesion subsets such as bifurcation lesions, calcified tortuous lesions, or diffuse
 long lesions. Real world registry is needed to test the feasibility and safety of BRS in
 these complex lesion subsets.
Inclusion Criteria:

 -  Subject must be between 19 and 70 years old.

 -  Patients with a significant lesion in a de novo coronary artery: a percent diameter
 stenosis (DS) 50% with 1) a positive history of recurrent angina pectoris; (2)
 objective signs of ischemia at rest (ECG changes) or during exercise test (or
 equivalent); or (3) abnormal results of any invasive functional diagnostic test (eg,
 fractional flow reserve) or a percent DS ≥70% even in the absence of the
 above-mentioned ischemic signs or symptoms.

 -  Patients are scheduled for coronary intervention

 -  He/she or his/her legally authorized representative provides written informed consent

 Exclusion Criteria:

 -  Experience of cardiopulmonary resuscitation

 -  Cardiogenic shock

 -  Expected survival less than 2 years

 -  Pregnancy or breast feeding

 -  Opinion of the investigator, would interfere with evaluation of study treatment or
 interpretation of patient safety or study results